Deal alert: We've never seen the Kindle Paperwhite this cheap!
Attention, bookworms! There's a last chance to grab the Kindle Paperwhite at a fantastic discount this Amazon Prime Day. Usually priced at $159.99, it's now available for just $124.99, a significant 22% markdown from retail and the lowest price we've ever tracked on the device.
Kindle Paperwhite for $124.99 (22% off)
This is the newest model of the Kindle Paperwhite, which scored a perfect 10 in our review. It offers a clear 7-inch E Ink display with improved contrast, making text sharp and readable, plus a faster dual-core processor ensures quick page turns and a responsive experience. It's designed with a long-lasting battery, allowing up to 12 weeks of reading on a single charge, depending on use.
Amazon Kindle Paperwhite (2024)
Amazon Kindle Paperwhite (2024)
The best standard e-reader in the Kindle lineup
The 2024 Amazon Kindle Paperwhite bumps the processing to make it the fastest Kindle to date. Quick page turns, a 7-inch anti-glare display, waterproof casing, and up to 12 weeks of battery life make for a solid reading experience.
See price at Amazon
Save
$35.00
Prime Deal
Water resistance is another key feature, with an IPX8-rated build that provides peace of mind around water. The adjustable front light system gives you the flexibility to read comfortably in various lighting conditions.
This Prime Day deal gives you a chance to experience the Kindle Paperwhite's refined design and enhanced reading features at an unbeatable price. Remember, these offers are exclusively for Amazon Prime members, but you can always sign up for a 30-day free trial to take advantage of this and other exciting deals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Piper Sandler Assumes Coverage of Kimberly-Clark (KMB) Stock, Gives Overweight
Kimberly-Clark Corporation (NASDAQ:KMB) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 18, Piper Sandler assumed coverage of the company's stock with an 'Overweight' rating and a price objective of $144, as reported by The Fly. As per the firm's analyst, the company remains well-placed for long-term growth given its exposure to premium personal care categories. Furthermore, the firm sees Kimberly-Clark Corporation (NASDAQ:KMB)'s valuation as undemanding. A stack of disposable diapers in the foreground with a mother and her baby in the background. Kimberly-Clark Corporation (NASDAQ:KMB) has also announced that it entered into an agreement with Suzano to form a strategic partnership, establishing a preeminent international tissue and professional products company and sharpening Kimberly-Clark Corporation (NASDAQ:KMB)'s emphasis on the higher growth, higher margin businesses. After the completion of the transaction, Kimberly-Clark Corporation (NASDAQ:KMB) will reduce its exposure to more volatile input costs. This will enhance its ability to deliver more predictable and consistent margins and profit growth. As per Nelson Urdaneta, Kimberly-Clark Corporation (NASDAQ:KMB)'s Chief Financial Officer, the transaction generates immediate returns and long-term shareholder value as the company captures the upside from a healthier international tissue and professional franchise and accelerates growth and innovation. While we acknowledge the potential of KMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Jim Cramer Notes Whirlpool Faces a 'Collaterally Damaged Situation'
Whirlpool Corporation (NYSE:WHR) is one of the stocks Jim Cramer recently talked about. Cramer called the company's quarter 'astonishing weak,' as he said: 'But UPS wasn't the only one. Whirlpool, which was supposed to be helped by the tariffs at least eventually, instead got walloped by them, crushed. Ugly. Whirlpool's last man standing when it comes to appliances, the only one that's still domiciled in this country, but the big appliance makers from South Korea and China, they're not dummies. They knew they'd struggle with the tariffs on their countries, so they front-loaded their inventory, shipping lots of appliances here ahead of time. Nonwarit/ Whirlpool (NYSE:WHR) designs, manufactures, and sells home appliances, including refrigerators, laundry machines, dishwashers, and small kitchen devices. While we acknowledge the potential of WHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
16 minutes ago
- Yahoo
Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial Anticipation
Alector Inc. (NASDAQ:ALEC) is one of the stocks under $10 to buy now. On July 28, Mizuho upgraded Alector from Neutral to Outperform, while raising the price target from $2.50 to $3.50. The decision reflected Mizuho's belief that the pessimism surrounding Alector's shares is excessive, especially considering the company's cash position of ~$350 million, which is roughly double its current valuation. Mizuho's confidence is also driven by feedback from key opinion leaders regarding latozinemab, which is Alector's lead asset for frontotemporal dementia/FTD, raising its probability of success from 50% to 60%. The firm favors the stock in anticipation of the Phase 3 data for latozinemab, expected in Q4 2025. The company is advancing its clinical pipeline, with the INFRONT-3 Phase 3 trial for latozinemab on schedule for topline data release in Q4 2025. A biotechnologist in a white lab coat manipulating genes in a laboratory. In Q1 2025, Alector reported revenue of $3.7 million, which fell short of the estimated $4.38 million. The revenue decline from $15.9 million in Q1 2024 was due to the completion of performance obligations related to the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial in late 2024. However, the net loss per share of $0.41 was better than the estimated loss of $0.48 per share. Alector Inc. (NASDAQ:ALEC) is a late-stage clinical biotechnology company that develops therapies that are focused on counteracting the devastating progression of neurodegenerative diseases. While we acknowledge the potential of ALEC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data
